| Seller: | Senn Chemicals AG |
| Buyer: | Granules India Limited
| Advisory sell side: | Hoffmann & Partner | Financial Advisory Kellerhals Carrard | Legal Advisory |
| Advisory buy side: | Stifel Nicolaus India | Financial Advisory Loyens & Loeff | Legal Advisory Deloitte | Financial & Tax Due Diligence Kroll | Valuation Advisory |
| Date announced: | 10-04-2025 |
Granules India Limited, a vertically integrated pharmaceutical company headquartered in India, has acquired Senn Chemicals AG, a Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in peptide synthesis and manufacturing. The acquisition was completed through Granules’ wholly owned subsidiary, Granules Peptides Private Limited.
Senn Chemicals, based in Dielsdorf, Switzerland, brings over 60 years of expertise in peptide therapeutics, with capabilities in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS and SPPS). The acquisition marks Granules' strategic entry into the fast-growing peptide API and CDMO segments and extends its scientific and development capabilities into next-generation therapeutic areas, including GLP-1 receptor agonists used in anti-diabetic and anti-obesity drugs.
The acquisition also significantly expands Granules’ footprint in Europe and strengthens its access to regulated markets and specialized talent.
About Senn Chemicals
Senn Chemicals AG, founded in 1963, is a leading CDMO for peptide and amino acid derivative (AAD) development and manufacturing. The company offers GMP and non-GMP capabilities for clients in pharmaceuticals, cosmetics, and theragnostics, covering projects from clinical trials to commercial scale.
About Granules India
Granules India Limited is a global pharmaceutical company involved in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). With 10 manufacturing sites (8 in India, 2 in the USA) and operations across 80+ countries, Granules holds approvals from major regulatory bodies including the US FDA, EDQM, WHO GMP, and others.
Comments